

NATCO PHARMA AUSTRALIA PTY LTD

ABN 40 601 572 301

FINANCIAL REPORT

FOR THE YEAR ENDED 31 MARCH 2024

NATCO PHARMA AUSTRALIA PTY LTD
ABN 40 601 572 301

CONTENTS

	Page No.
Directors' Report	2
Auditor's Independence Declaration	4
Statement of Profit or Loss	5
Statement of Comprehensive Income	6
Statement of Financial Position	7
Statement of Changes in Equity	8
Statement of Cash Flows	9
Notes to the Financial Statements	10
Directors' Declaration	15
Independent Auditor's Report	16

Natco Pharma Australia Pty Ltd ABN 40 601 572 301
Financial Report for the Year Ended 31 March 2024
DIRECTORS' REPORT

Your directors present their report on the company for the year ended 31 March 2024.

Directors

The names of the directors in office at any time during or since the end of the year are:

Subba Rao Mente
Alakkudi Sundararaman
Apparao Sannidhanam Veera Venkata Narasimha

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

Review of Operations

The loss of the company for the year after providing for income tax amounted to \$84,376 (2023: loss of \$132,757).

A review of the operations of the company during the year and the results of those operations are as follows:

Significant Changes in the State of Affairs

No significant changes in the company's state of affairs occurred during the year.

Principal Activities

The principal activities of the company during the year were research and development activities in relation to generic pharmaceuticals.

No significant change in the nature of these activities occurred during the year.

Likely Developments and Expected Results of Operations

Likely developments in the operations of the company and the expected results of those operations in future years have not been included in this report as the inclusion of such information is likely to result in unreasonable prejudice to the company.

Environmental Regulation

The company's operations are not regulated by any significant environmental regulation under a law of the Commonwealth or of a state or territory.

Dividends

No dividends have been paid or declared since the start of the year.

Options

No options over issued shares or interests in the company were granted during or since the end of the year and there were no options outstanding at the date of this report.

Indemnification of Officers

No indemnities have been given or insurance premiums paid, during or since the end of year, for any person who is or has been an officer or auditor of the company.

DIRECTORS' REPORT

Proceedings on Behalf of the Company

No person has applied for leave of court to bring proceedings on behalf of the company or intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or any part of those proceedings.

The company was not a party to any such proceedings during the year.

This directors' report is signed in accordance with a resolution of the Board of Directors:

Director



Apparao Sannidhanam Veera Venkata Narasimha

Dated this

23rd

day of

April

2024



23 April 2024

The Directors

Natco Pharma Australia Pty Ltd
Level 16, 414 La Trobe Street
Melbourne VIC 3000

Dear Directors

Australian Auditing Standards require that there must be a clear understanding in writing between the auditor and the client as to the extent of the audit duties to be performed. Accordingly, we are pleased to confirm our acceptance and our understanding of the audit engagement by means of this letter.

The objective and scope of the audit

You have requested that we audit the financial report of Natco Pharma Australia Pty Ltd (the "Company") which comprises the statement of financial position as at 31 March 2024, and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, notes to the financial statements comprising significant accounting policies and other explanatory information, and the Directors' declaration.

The objectives of our audit are to obtain reasonable assurance about whether the financial report as a whole, is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

You have advised us that the financial report will be a special purpose financial report prepared in accordance with the accounting policies described in Note 1.

The responsibilities of the auditor

We will conduct our audit in accordance with Australian Auditing Standards. Those standards require that we comply with ethical requirements. As part of an audit in accordance with Australian Auditing Standards, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. However, we will communicate to you in writing concerning any significant deficiencies in internal control relevant to the audit of the financial report that we have identified during the audit.

Brisbane
Level 15
240 Queen Street
Brisbane QLD 4000
T + 61 7 3085 0888

Melbourne
Level 10
530 Collins Street
Melbourne VIC 3000
T + 61 3 8635 1800

Perth
Level 18
197 St Georges Terrace
Perth WA 6000
T + 61 8 6184 5980

Sydney
Level 7, Aurora Place
88 Phillip Street
Sydney NSW 2000
T + 61 2 8059 6800



- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.
- evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.
- in accordance with Australian Auditing Standard ASA 800 *Special Considerations – Audits of Financial Reports Prepared in Accordance with Special Purpose Frameworks*, without modifying our opinion, we are required to include a paragraph alerting users to the basis of accounting used in the preparation of the financial statements. Our auditor's report will therefore contain an Emphasis of Matter section highlighting to readers that special purpose financial statements may not be suitable for another purpose.

Because of the inherent limitations of an audit, together with the inherent limitations of internal control, there is an unavoidable risk that some material misstatements may not be detected, even though the audit is properly planned and performed in accordance with Australian Auditing Standards.

Reporting

Throughout the engagement we will report to you both formally and informally in accordance with Australian Auditing Standards, and in line with our "no surprises" culture. Initially our audit approach will be communicated to you in an audit plan, and as the circumstances dictate throughout the engagement, we may amend our scope, alter our audit approach and/or propose matters of special emphasis.

In addition to the audit plan we will also provide an audit report which may need to be amended in light of our audit findings. In circumstances where a modified Auditor's Opinion is considered we will advise the details to you in a timely manner and prior to the issuance of our report.

Finally, at the completion of the engagement we will issue a closing report describing any matters arising from the audit, as a result of the audit procedures performed, as well as communicating any relevant issues required to be reported to those charged with governance.

The responsibilities of those charged with governance

Our audit will be conducted on the basis that those charged with governance acknowledge and understand that they have responsibility:

1. for the preparation of the financial report that present fairly in accordance with the accounting policies described in note 1.
2. for such internal control as the those charged with governance determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error, and
3. to provide us with:
 - access to all information of which those charged with governance and management are aware that is relevant to the preparation of the financial report such as records, documentation and other matters
 - additional information that we may request from those charged with governance and management for the purpose of the audit

- unrestricted access to persons within the entity from whom we determine it necessary to obtain audit evidence, and
- where applicable, timely copies of documents expected to be issued as 'Other Information' which is consistent with all other aspects of the financial report.

As part of our audit process, we will request from management and, where appropriate, those charged with governance, written confirmation concerning representations made to us in connection with the audit.

Fees

We estimate a fee of \$5,635 to complete the review of audit for year ending 31 March 2024.

Our fees, which will be billed as work progresses, are based on the time required by the individuals assigned to the engagement plus out-of-pocket expenses, as outlined in our separate fee proposal letter. Individual hourly rates vary according to the degree of responsibility involved and the experience and skill required.

Independence

We confirm that, to the best of our knowledge and belief, we currently meet the independence requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) in relation to the audit of the financial report. In conducting our audit of the financial report, should we become aware that we have contravened the independence requirements, we shall notify you on a timely basis.

The Code includes specific restrictions on the employment relationships that can exist between the audited entity and its auditor. To assist us in meeting the independence requirements and to the extent permitted by law and regulation, we request that you discuss with us:

- the provision of services offered to the entity by SW Audit or any affiliated members of ShineWing International Limited prior to engaging or accepting the service, and
- the prospective employment opportunities of any current or former partner or professional employee of SW Audit or any affiliated members of ShineWing International Limited prior to the commencement of formal employment discussions with the current or former partner or professional employee.

Other

The terms and conditions of business as documented in the attached Terms and Conditions (Assurance Engagements) apply in respect of the services described in this engagement letter.

SW Audit is a member firm of ShineWing International Limited which enables us access to an extensive global network.

We look forward to full co-operation with your staff and we trust that they will make available to us any records, documentation and other information requested in connection with our audit.

We may use resources from an associated entity, Vitae International, based in India, to perform limited audit procedures to support the services performed by our local team. We alone will be responsible to you for the performance of the services and other obligations in this engagement letter.

Please sign and return the attached copy of this letter to indicate your acknowledgement of and agreement with, the arrangements for our audit of the financial report including our respective responsibilities, and the COVID-19 overlay.

Please note that should we not receive a signed acknowledgement of this engagement letter and you commence communication with us in relation to the audit of the financial report, we will deem your acceptance of the contents of this engagement letter and supporting Terms and Conditions (Assurance Engagements).

Yours sincerely



René Muller

Partner

SW Audit (formerly ShineWing Australia)

Acknowledged and authorised on behalf of Natco Pharma Australia Pty Ltd by:

S.V.V.N. Apparao

Print name

Director

Title



Signature

23/04/2024

Date



NATCO PHARMA AUSTRALIA PTY LTD
ABN 40 601 572 301

STATEMENT OF PROFIT OR LOSS
FOR THE YEAR ENDED 31 MARCH 2024

	Note	2024 \$	2023 \$
Other expenses	2	(84,376)	(132,757)
Research and Development Costs		-	-
		<hr/>	<hr/>
Loss before income tax		(84,376)	(132,757)
Income tax expense		-	-
		<hr/>	<hr/>
Loss for the year		<u>(84,376)</u>	<u>(132,757)</u>
Loss attributable to members of the company		<u>(84,376)</u>	<u>(132,757)</u>

These statements should be read in conjunction with the notes to the financial statements.

NATCO PHARMA AUSTRALIA PTY LTD
ABN 40 601 572 301

STATEMENT OF FINANCIAL POSITION

AS AT 31 MARCH 2024

	Note	2024 \$	2023 \$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	3	84,891	65,098
Trade and other receivables	4	1,691	2,653
TOTAL CURRENT ASSETS		86,582	67,751
TOTAL ASSETS		86,582	67,751
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	5	21,354	18,147
TOTAL CURRENT LIABILITIES		21,354	18,147
TOTAL LIABILITIES		21,354	18,147
NET ASSETS		65,228	49,604
EQUITY			
Issued capital	6	3,908,572	3,808,572
Accumulated losses		(3,843,344)	(3,758,968)
TOTAL EQUITY		65,228	49,604

These statements should be read in conjunction with the notes to the financial statements.

NATCO PHARMA AUSTRALIA PTY LTD
ABN 40 601 572 301

STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2024

	2024	2023
	\$	\$
Loss for the year	(84,376)	(132,757)
Other comprehensive income	-	-
Total other comprehensive income for the year	-	-
Total comprehensive loss for the year	<u>(84,376)</u>	<u>(132,757)</u>
Total comprehensive loss attributable to members of the company	<u>(84,376)</u>	<u>(132,757)</u>

These statements should be read in conjunction with the notes to the financial statements.

NATCO PHARMA AUSTRALIA PTY LTD
ABN 40 601 572 301

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2024

	Issued Capital \$	Accumulated losses \$	Total \$
Balance at 1 April 2019	978,572	(984,374)	(5,802)
Comprehensive income			
Loss for the year	-	(389,758)	(389,758)
Total comprehensive income for the year attributable to the member of the company	-	(389,758)	(389,758)
Transactions with the owner, in capacity as owner and other transfers			
Natco Pharma Limited	80,000	-	80,000
Total transactions with the owner and other transfers	80,000	-	80,000
Balance at 31 March 2020	1,058,572	(1,374,132)	(315,560)
Balance at 1 April 2020	1,058,572	(1,374,132)	(315,560)
Comprehensive income			
Loss for the year	-	(1,495,557)	(1,495,557)
Total comprehensive income for the year attributable to the member of the company	-	(1,495,557)	(1,495,557)
Transactions with the owner, in capacity as owner and other transfers			
Natco Pharma Limited	850,000	-	850,000
Total transactions with the owner and other transfers	850,000	-	850,000
Balance at 31 March 2021	1,908,572	(2,869,689)	(961,117)
Balance at 1 April 2021	1,908,572	(2,869,689)	(961,117)
Comprehensive income			
Loss for the year	-	(756,522)	(756,522)
Total comprehensive income for the year attributable to the member of the company	-	(756,522)	(756,522)
Transactions with the owner, in capacity as owner and other transfers			
Natco Pharma Limited	1,700,000	-	1,700,000
Total transactions with the owner and other transfers	1,700,000	-	1,700,000
Balance at 31 March 2022	3,608,572	(3,626,211)	(17,639)

STATEMENT OF CHANGES IN EQUITY CONTINUED

Balance at 1 April 2022	3,608,572	(3,626,211)	(17,639)
Comprehensive income			
Loss for the year	-	(132,757)	(132,757)
Total comprehensive income for the year attributable to the member of the company	<u>-</u>	<u>(132,757)</u>	<u>(132,757)</u>
Transactions with the owner, in capacity as owner and other transfers			
Natco Pharma Limited	200,000	-	200,000
Generic Partners Holding Co Pty Ltd	-	-	-
Sanjiv Puri	-	-	-
Total transactions with the owner and other transfers	<u>200,000</u>	<u>-</u>	<u>200,000</u>
Balance at 31 March 2023	<u><u>3,808,572</u></u>	<u><u>(3,758,968)</u></u>	<u><u>49,604</u></u>
Balance at 1 April 2023	3,808,572	(3,758,968)	49,604
Comprehensive income			
Loss for the year	-	(84,376)	(84,376)
Total comprehensive income for the year attributable to the member of the company	<u>-</u>	<u>(84,376)</u>	<u>(84,376)</u>
Transactions with the owner, in capacity as owner and other transfers			
Natco Pharma Limited	100,000	-	100,000
Generic Partners Holding Co Pty Ltd	-	-	-
Sanjiv Puri	-	-	-
Total transactions with the owner and other transfers	<u>100,000</u>	<u>-</u>	<u>100,000</u>
Balance at 31 March 2024	<u><u>3,908,572</u></u>	<u><u>(3,843,344)</u></u>	<u><u>65,228</u></u>

These statements should be read in conjunction with the notes to the financial statements.

NATCO PHARMA AUSTRALIA PTY LTD
ABN 40 601 572 301

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2024

	Note	2024 \$	2023 \$
Cash flows from operating activities			
Payment to suppliers		(85,134)	(143,926)
Receipts from collection of receivables		4,927	4,898
Net cash used in operating activities	7	(80,207)	(139,028)
Cash flows from financing activities			
Capital contribution		100,000	200,000
Net cash provided by financing activities		100,000	200,000
Net increase / (decrease) in cash held		19,793	60,972
Cash and cash equivalents at beginning of financial year		65,098	4,126
Cash and cash equivalents at end of financial year	3	84,891	65,098

These statements should be read in conjunction with the notes to the financial statements.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Natco Pharma Australia Pty Ltd is a company limited by shares, incorporated and domiciled in Australia.

The financial statements were authorised for issue on 26 April 2024 by the directors of the company.

Basis of Preparation

The directors have prepared the financial statements on the basis that the company is a non-reporting entity because there are no users dependent on general purpose financial statements. The financial statements are therefore special purpose financial statements that have been prepared in order to meet the needs of the shareholders. The company is a for-profit entity for financial reporting purposes under Australian Accounting Standards which was incorporated on 1 September 2014.

The financial statements have been prepared in accordance with the mandatory Australian Accounting Standards and the significant accounting policies disclosed below, which the directors have determined are appropriate to meet the needs of members. Such accounting policies are consistent with the previous period unless stated otherwise.

The financial statements, except for the cash flow information, have been prepared on an accruals basis and are based on historical costs unless otherwise stated in the notes. The amounts presented in the financial statements have been rounded to the nearest dollar.

Accounting Policies

a. Impairment of Assets

At the end of each reporting period, the company assesses whether there is any indication that an asset may be impaired. The assessment will include considering external sources of information and internal sources of information including dividends received from subsidiaries, associates or jointly controlled entities deemed to be out of pre-acquisition profits. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, to the asset's carrying amount. Any excess of the asset's carrying amount over its recoverable amount is recognised immediately in profit or loss, unless the asset is carried at a revalued amount. Any impairment loss of a revalued asset is treated as a revaluation decrease.

Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

b. Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within short-term borrowings in current liabilities on the statement of financial position.

c. Revenue and Other Income

Revenue is measured at the fair value of the consideration received or receivable after taking into account any trade discounts and volume rebates allowed. Any consideration deferred is treated as the provision of finance and is discounted at a rate of interest that is generally accepted in the market for similar arrangements. The difference between the amount initially recognised and the amount ultimately received is interest revenue.

Interest revenue is recognised using the effective interest method, which for floating rate financial assets is the rate inherent in the instrument.

Revenue recognition relating to the provision of services is determined with reference to the stage of completion of the transaction at the end of the reporting period and where outcome of the contract can be estimated reliably. Stage of completion is determined with reference to the services performed to date as a percentage of total anticipated services to be performed. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent that related expenditure is recoverable.

All revenue is stated net of the amount of goods and services tax.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

d. **Trade and Other Receivables**

Trade and other receivables include amounts due from customers for goods sold and services performed in the ordinary course of business. Receivables expected to be collected within 12 months of the end of the reporting period are classified as current assets. All other receivables are classified as non-current assets.

Trade and other receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any provision for impairment.

e. **Trade and Other Payables**

Trade and other payables represent the liabilities for goods and services received by the entity that remain unpaid at the end of the reporting period. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

f. **Goods and Services Tax (GST)**

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to, the ATO are presented as operating cash flows included in receipts from customers or payments to suppliers.

g. **Intangible Assets**

Patent costs have been recognised as an Intangible Asset on the basis that they will provide future economic benefits. They have been depreciated according to the effective life of a standard patent of 20 years on a diminishing value basis.

h. **Comparative Figures**

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year. The comparative figures in this report are for the period 1 April 2022 to 31 March 2023.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

NOTE 2: LOSS FOR THE YEAR

	2024	2023
	\$	\$
Other expenses		
Accountancy fees	12,330	11,960
Auditors' remuneration	12,770	11,219
Bad Debts	83	0
Bank charges	120	420
Consulting Fees	2,750	7,710
Directors Fee	12,000	12,000
Filing fees	310	290
Interest Expense	3	0
TGA Fees	44,010	89,159
	84,376	132,757
	84,376	132,757

NOTE 3: CASH AND CASH EQUIVALENTS

	2024	2023
	\$	\$
Cash at bank	84,891	65,098
	84,891	65,098
	84,891	65,098

Reconciliation of cash

Cash at the end of the financial year as shown in the statement of cash flows is reconciled to items in the statement of financial position as follows:

Cash and cash equivalents	84,891	65,098
	84,891	65,098
	84,891	65,098

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

NOTE 4: TRADE AND OTHER RECEIVABLES

	2024	2023
	\$	\$
CURRENT		
Other receivables	1,691	2,653
	1,691	2,653
	1,691	2,653

NOTE 5: TRADE AND OTHER PAYABLES

	2024	2023
	\$	\$
CURRENT		
Trade creditors	3,949	1,485
Accrued expenses	17,405	16,662
	20,804	18,147
	20,804	18,147

NOTE 6: ISSUED CAPITAL

	2024	2023
	\$	\$
a. 3,908,572 fully paid ordinary shares	3,908,572	3,808,572
	3,908,572	3,808,572

The company has authorised share capital amounting to 3,908,572 (2023: 3,808,572) ordinary shares of no-par value. During the year, the parent company Natco Pharma Limited has acquired 100,000 fully paid ordinary shares of \$1 AUD each with effect from 15 March 2024.

Ordinary shares participate in dividends and the proceeds on winding up of the company in proportion to the number of shares held.

At the shareholders' meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

NOTE 7: CASH FLOW INFORMATION

	2024	2023
	\$	\$
Reconciliation of Cash Flow from Operations with Loss after Income Tax		
Loss after income tax	(84,376)	(132,757)
Non-cash flows in profit:		
Changes in assets and liabilities:		
– Decrease/(Increase) in receivables	1,012	(607)
– (Decrease)/Increase in payables	2,657	(5,662)
	(80,707)	(139,026)
	(80,707)	(139,026)

NOTE 8: SUBSEQUENT EVENTS

There have been no subsequent events after the reporting period.

NOTE 9: GOING CONCERN

The company generated a loss of \$84,376 in the year and had net assets of \$65,228 at 31 March 2024. Notwithstanding the loss and the net liabilities, the entity raised capital amounting to \$100,000 and has the ongoing support of the parent entity. The Directors therefore believe the Going Concern basis or preparation is appropriate and the Company will be able to repay their debts as and when they fall due.

NOTE 10: COMPANY DETAILS

The company's parent entity is Natco Pharma Limited, a listed entity incorporated in India.

The registered office of the company is:

Blue Rock Australia Pty Ltd
Rialto, Level 2 Podium East, 525 Collins Street
MELBOURNE VIC 3000

The principal place of business is:

Natco Pharma Australia Pty Ltd
6 Morotai Avenue
ASHBURTON VIC 3147

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

DIRECTORS' DECLARATION

In accordance with a resolution of the directors of Natco Pharma Australia Pty Ltd, the directors have determined that the company is not a reporting entity and that this special purpose financial report should be prepared in accordance with the accounting policies described in Note 1 to the financial statements.

The directors of the company declare that:

1. The financial statements and notes, as set out on pages 5 to 14:
 - a. comply with Australian Accounting Standards; and
 - b. Presents fairly the company's financial position as at 31 March 2024 and of its performance for the year ended on that date in accordance with the accounting policies described in Note 1 to the financial statements.
2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.



Director

A handwritten signature in black ink, appearing to read "Apparao Sannidhanam Veera Venkata Narasimha".

Apparao Sannidhanam Veera Venkata Narasimha

Dated this

28th

day of

April

2024

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NATCO PHARMA AUSTRALIA PTY LTD

We have audited the accompanying financial report, being a special purpose financial report, of Natco Pharma Australia Pty Ltd (the company), which comprises the statement of financial position as at 31 March 2024, the statement of profit or loss, statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Directors' Responsibility for the Financial Report

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view and have determined that the accounting policies described in Note 1 of the financial report are appropriate to meet the requirements of the *Corporations Act 2001* and to meet the needs of the members. The directors' responsibility also includes such internal control as the directors determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We have conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance about whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation of the financial report that gives a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Independence

In conducting our audit, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of Natco Pharma Australia Pty Ltd, would be in the same terms if given to the directors as at the time of the auditor's report.

Opinion

In our opinion the financial report of Natco Pharma Australia Pty Ltd is in accordance with the *Corporations Act 2001*, including:

- a. giving a true and fair view of the company's financial position as at 31 March 2024 and of its performance for the period ended on that date in accordance with the accounting policies described in Note 1; and
- b. complying with Australian Accounting Standards to the extent described in Note 1 and complying with the *Corporations Regulations 2001*.


Basis of Accounting

Without modifying our opinion, we draw attention to Note 1 of the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the directors' financial reporting responsibilities under the *Corporations Act 2001*. As a result, the financial report may not be suitable for another purpose.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

Name of firm: ShineWing Australia Pty Ltd

Name of partner: Rene Muller



Address: Level 10, 530 Collins Street, MELBOURNE VIC 3000

Dated this 2nd day of May 2024